FY2019 EPS Estimates for Sucampo Pharmaceuticals, Inc. Lifted by Analyst (SCMP)

(NASDAQ:SCMP). Prelude Mngmt Ltd Liability Com reported 0.01% of its portfolio in Sucampo Pharmaceuticals, Inc. They issued a "buy" rating and a $14.00 price target for the company. The lowest target is $16.0 while the high is $19.0.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported $0.27 EPS for the quarter, topping the Zacks' consensus estimate of $0.25 by $0.02. Sucampo Pharmaceuticals had a positive return on equity of 74.58% and a negative net margin of 60.24%. The business had revenue of $61.27 million during the quarter, compared to the consensus estimate of $58.05 million. During the same quarter in the previous year, the company posted $0.30 earnings per share. Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) has declined 5.30% since January 7, 2017 and is downtrending.

A number of other research analysts have also recently commented on SCMP.

Sucampo Pharmaceuticals, Inc. (SCMP) stock is now trading 61.91% away from its average-price of 200 days while it maintained a distance of 37.32% from its 50 Days Moving Average and 7.43% compared with the 20 Day Moving Average. Maxim Group restated a buy rating and set a $23.00 price target on shares of Sucampo Pharmaceuticals in a research note on Thursday, November 2nd. Finally, Globeflex Capital L P increased its stake in shares of Sucampo Pharmaceuticals by 0.3% in the second quarter. They issued a "buy" rating and a $14.00 price objective for the company.

Analysts have given a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range). (NASDAQ SCMP) traded down $0.35 during mid-day trading on Friday, hitting $18.05. SCMP has a beta of 1.46 and therefore an above average level of market volatility. SCMP has a current ratio of 5.10 compared to 6.30 for IONS. Sucampo Pharmaceuticals has a 1-year low of $9.30 and a 1-year high of $18.75. The company has market cap of $223.66 million. To answer this question, we will compare the two companies across various metrics including growth, profitability, risk, return, dividends, and valuation. The stock of Sucampo Pharmaceuticals, Inc. Following the completion of the transaction, the insider now directly owns 52,023 shares of the company's stock, valued at $858,379.50. Finally, Aperio Group LLC bought a new stake in Sucampo Pharmaceuticals in the third quarter valued at about $137,000. Vanguard Group Inc. now owns 1,646,348 shares of the biopharmaceutical company's stock valued at $17,287,000 after buying an additional 189,561 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Sucampo Pharmaceuticals by 13.0% in the 3rd quarter. Institutional investors own 65.29% of the company's stock. The share price has moved forward from its 20 days moving average, trading at a distance of 7.43% and stays 37.32% away from its 50 days moving average. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

The Boeing Company (BA) surged 4.1% yesterday to close its trading session at $308.84.

WARNING: "Sucampo Pharmaceuticals (NASDAQ:SCMP) Downgraded by UBS Group to "Neutral" was originally reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another publication, it was illegally copied and reposted in violation of global trademark and copyright law.

Ameriprise Financial Inc. lifted its holdings in Sucampo Pharmaceuticals, Inc.

Rockville, MD based Sucampo Pharmaceuticals, Inc.is a biopharmaceutical company. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Latest News